美国安进地诺单抗多少钱一支？

It is the first approved monoclonal antibody that specifically targets RANK ligand. It specifically targets nuclear factor κB receptor activator ligand (RANKL), inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density. Denosumab was approved in 2010 for use in patients with solid tumor bone metastases to prevent fracture-related events. Xgeva is not suitable for preventing bone-related events in patients with multiple myeloma (MM). In 2013, the FDA approved a new indication for denosumab for the treatment of adult patients and skeletally mature adolescent patients with giant cell tumor of bone (GCTB) that is unresectable or whose surgical resection may cause serious complications. The drug is also the first and only GCTB treatment drug approved by the FDA.

Denosumab's original drug is produced by Amgen in the United States. Amgen was founded in 1980 by a group of scientists and venture capitalists. Amgen is principally engaged in the discovery, development, production and sales of innovative drugs for human use, and is committed to exploring the potential of biotechnology for the treatment of patients with serious diseases. As one of the world's largest biopharmaceutical companies, Amgen is a leader in the global biopharmaceutical industry. It has strong R&D capabilities and product advantages. It insists on developing in the field of biotechnology for disease treatment. Its main fields include human genome, cancer, neuroscience and small molecule chemistry. How much does Amgen denosumab cost in the United States?

Xgeva produced by Amgen in the United States is exported to Turkey at a cheaper price. The specification is 120mg and the price is about $1,500. For detailed price information, please consult the medical companion passenger service.

Recommended related hot articles: /newsDetail/85819.html